Hologic, Inc(HOLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 31.54 | EPS (ttm) | 2.41 | Insider Own | 1.55% | Shs Outstand | 223.1M | Perf Week | - |
| Market Cap | 16.97B | Forward P/E | 15.9 | EPS next Y | 8.02% | Insider Trans | -0.21% | Shs Float | 219.8M | Perf Month | 1.28% |
| Enterprise Value | 17.12B | PEG | 2.52 | EPS next Q | 1.05 | Inst Own | 96.49% | Short Float | 3.73% | Perf Quarter | 1.13% |
| Income | 0.54B | P/S | 4.11 | EPS this Y | 3.87% | Inst Trans | - | Short Ratio | 1.85 | Perf Half Y | 15.31% |
| Sales | 4.13B | P/B | 3.23 | EPS next 5Y | 6.32% | ROA | 6.07% | Short Interest | 8.20M | Perf YTD | 2.04% |
| Book/sh | 23.51 | P/C | 7.18 | EPS past 3/5Y | -21.45% -10.02% | ROE | 10.86% | 52W High | -0.08% ($76.07) | Perf Year | 24.89% |
| Cash/sh | 10.59 | P/FCF | 17.73 | Sales past 3/5Y | -5.53% 1.66% | ROIC | 7.01% | 52W Low | 46.45% ($51.90) | Perf 3Y | -8.27% |
| Dividend Est. | - | EV/EBITDA | 13.57 | EPS Y/Y TTM | -23.89% | Gross Margin | 55.62% | Volatility(W/M) | 0.22% 0.27% | Perf 5Y | 1.73% |
| Dividend TTM | - | EV/Sales | 4.15 | Sales Y/Y TTM | 2.17% | Oper. Margin | 23.66% | ATR (14) | 0.23 | Perf 10Y | 112.62% |
| Dividend Ex-Date | - | Quick Ratio | 3.32 | EPS Q/Q | -8.44% | Profit Margin | 13.18% | RSI (14) | 68.74 | Recom | 3.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.04 | Sales Q/Q | 2.54% | SMA20 | 0.71% ($75.47) | Beta | 0.73 | Target Price | $76 |
| Payout | - | Debt/Eq | 0.48 | Earnings | 2026/1/29 | SMA50 | 0.96% ($75.29) | Rel Volume | 0 | Prev Close | $76.01 |
| Employees | 7070 | LT Debt/Eq | 0.48 | EPS/Sales Surpr. | -5.08% -2.2% | SMA200 | 6.64% ($71.28) | Avg Volume(3M) | 4.44M | Price | $76.01 |
| IPO | 1990/3/1 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🩺 This company is a medical device and diagnostics company focused on women's health. It supplies medical devices and diagnostic solutions specialized in women's health, including breast imaging diagnostics (mammography), molecular diagnostics, gynecological surgical instruments, and bone density testing. It is one of the leading companies in the women's health medical device sector.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
HOLX makes money exceptionally well
Of every $100 in sales, $23.66 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +3.9% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,357. Peers typically go for $1,577.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +1.7%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 96.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #7 of 52 in the industry
Based on market cap of $17B.
FAQ
What kind of company is HOLX?
HOLX belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of HOLX?
The market cap of HOLX is approximately $17.0B, ranking 677 within its sector.
What is the P/E ratio of HOLX?
HOLX has a P/E ratio of approximately 31.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HOLX?
HOLX has recorded a 52-week high of $76.07 and a low of $51.90.
